Overall rank by patents
#30,323
of 49,997 tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 2 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Tarsus ranks #30,323 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 2 technology areas.
USPTO PatentsView assignee plate
Corpus R30323 · US Corporation #30,323 · 9 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Taisei Corporation (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Alere SAN Diego · near
39 score
Cynora · near
39 score
Immunocore · near
39 score
Institute OF… · near
39 score
Tarsus Pharmaceuticals · this assignee
39 score
3D Lighting… · lowest
7 score
What this shows Tarsus's Innovation Score is 38.8/100 (top 40% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Tarsus Pharmaceuticals, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2020. By volume, Tarsus sits between Taisei Corporation and TearOptix, Inc..
Tarsus Pharmaceuticals, Inc. shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Taisei Corporation
9 patents
Takara Bio Europe AB
9 patents
Takeda Pharmaceuticals U.S.A., Inc.
9 patents
Tangent Co., Ltd.
9 patents
Taurus International Manufacturing, Inc.
9 patents
Teak Isle Manufacturing, Inc.
9 patents
Teal Drones, Inc.
9 patents
TearOptix, Inc.
9 patents
Tarsus Pharmaceuticals, Inc.
9 patents
What this shows Tarsus holds 9 patents at rank #30,365, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #30,365 in granted patent volume.
Other assignees with the most granted patents in Tarsus's primary technology class.
Two PlainPatent-derived peer sets for Tarsus, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (39 here).
Tarsus's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
39 Top 40% higher than 60% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 11.1% |
| 2021 | 1 | 11.1% |
| 2023 | 3 | 33.3% |
| 2024 | 1 | 11.1% |
| 2025partial year | 3 | 33.3% |
Top 2 of 2 technology areas
Overall rank by patents
#30,323
of 49,997 tracked assignees
38.8 out of 100
What to do with this data
Tarsus Pharmaceuticals, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.